{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:28:55Z","timestamp":1792412935310,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,12,18]],"date-time":"2013-12-18T00:00:00Z","timestamp":1387324800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2013,12,18]],"date-time":"2013-12-18T00:00:00Z","timestamp":1387324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>The aim of this study was to determine the prevalence of gastrointestinal and behavioural symptoms occurring before (anticipatory\/associative) and after methotrexate (MTX) administration, termed MTX intolerance, in rheumatoid (RA) and psoriatic arthritis (PsA).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>Methotrexate Intolerance Severity Score (MISS), previously validated in juvenile idiopathic arthritis patients, was used to determine MTX intolerance prevalence in 291 RA\/PsA patients. The MISS consisted of four domains: abdominal pain, nausea, vomiting and behavioural symptoms, occurring upon, prior to (anticipatory) and when thinking of MTX (associative). MTX intolerance was defined as \u22656 on the MISS with \u22651 point on anticipatory and\/or associative and\/or behavioural items.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>A total of 123 patients (42.3%) experienced at least one gastrointestinal adverse effect. The prevalence of MTX intolerance was 11%. MTX intolerance prevalence was higher in patients on parenteral (20.6%) than on oral MTX (6.2%) (p\u2009&lt;\u20090.001).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusion<\/jats:title>\n                        <jats:p>Besides well-known gastrointestinal symptoms after MTX, RA and PsA patients experienced these symptoms also before MTX intake. RA and PsA patients on MTX should be closely monitored with the MISS for early detection of MTX intolerance, in order to intervene timely and avoid discontinuation of an effective treatment.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar4413","type":"journal-article","created":{"date-parts":[[2013,12,18]],"date-time":"2013-12-18T10:02:54Z","timestamp":1387360974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis"],"prefix":"10.1186","volume":"15","author":[{"given":"Maja","family":"Bulatovi\u0107 \u0106alasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar FC","family":"van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjonne CW","family":"Creemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Custers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonius HM","family":"Heurkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Maarten","family":"van Woerkom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico M","family":"Wulffraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,18]]},"reference":[{"key":"4079_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TW: Rheumatoid arthritis. Lancet. 2010, 376: 1094-1108. 10.1016\/S0140-6736(10)60826-4.","journal-title":"Lancet"},{"key":"4079_CR2","first-page":"S132","volume":"28","author":"A Ceponis","year":"2010","unstructured":"Ceponis A, Kavanaugh A: Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol. 2010, 28: S132-S137.","journal-title":"Clin Exp Rheumatol"},{"key":"4079_CR3","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010, 69: 964-975. 10.1136\/ard.2009.126532.","journal-title":"Ann Rheum Dis"},{"key":"4079_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","volume":"71","author":"L Gossec","year":"2012","unstructured":"Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Ca\u00f1ete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landew\u00e9 R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP: European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012, 71: 4-12. 10.1136\/annrheumdis-2011-200350.","journal-title":"Ann Rheum Dis"},{"key":"4079_CR5","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1136\/ard.2008.094474","volume":"68","author":"K Visser","year":"2009","unstructured":"Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, Bombardier C, Carmona L, van der Heijde D, Bijlsma JW, Boumpas DT, Canhao H, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF, Mart\u00edn-Mola EM, Mielants H, M\u00fcller-Ladner U, Murphy G, \u00d8stergaard M, Pereira IA, Ramos-Remus C, Valentini G, Zochling J, Dougados M: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009, 68: 1086-1093. 10.1136\/ard.2008.094474.","journal-title":"Ann Rheum Dis"},{"key":"4079_CR6","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1136\/ard.2008.106617","volume":"69","author":"SM Verstappen","year":"2010","unstructured":"Verstappen SM, Bakker MF, Heurkens AH, van der Veen MJ, Kruize AA, Geurts MA, Bijlsma JW, Jacobs JW, Utrecht Rheumatoid Arthritis Cohort Study Group: Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis. 2010, 69: 1044-1048. 10.1136\/ard.2008.106617.","journal-title":"Ann Rheum Dis"},{"key":"4079_CR7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.7326\/0003-4819-157-4-201208210-00020","volume":"157","author":"JW Jacobs","year":"2012","unstructured":"Jacobs JW, Bakker MF, Bijlsma JW: Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis. Ann Intern Med. 2012, 157: 300-","journal-title":"Ann Intern Med"},{"key":"4079_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF00290521","volume":"15","author":"A Schnabel","year":"1996","unstructured":"Schnabel A, Herlyn K, Burchardi C, Reinhold-Keller E, Gross WL: Long-term tolerability of methotrexate at doses exceeding 15\u00a0mg per week in rheumatoid arthritis. Rheumatol Int. 1996, 15: 195-200. 10.1007\/BF00290521.","journal-title":"Rheumatol Int"},{"key":"4079_CR9","first-page":"1850","volume":"20","author":"RJ McKendry","year":"1993","unstructured":"McKendry RJ, Dale P: Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol. 1993, 20: 1850-1856.","journal-title":"J Rheumatol"},{"key":"4079_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/art.23144","volume":"58","author":"J Braun","year":"2008","unstructured":"Braun J, Kastner P, Flaxenberg P, Wahrisch J, Hanke P, Demary W, von Hin\u00fcber U, Rockwitz K, Heitz W, Pichlmeier U, Guimbal-Schmolck C, Brandt A, MC-MTX.6\/RH Study Group: Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008, 58: 73-81. 10.1002\/art.23144.","journal-title":"Arthritis Rheum"},{"key":"4079_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/art.1780350203","volume":"35","author":"JM Kremer","year":"1992","unstructured":"Kremer JM, Phelps CT: Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum. 1992, 35: 138-145. 10.1002\/art.1780350203.","journal-title":"Arthritis Rheum"},{"key":"4079_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/ard.2009.113308","volume":"69","author":"E Lie","year":"2010","unstructured":"Lie E, van der Heijde D, Uhlig T, Heiberg MS, Koldingsnes W, Rodevand E, Kaufmann C, Mikkelsen K, Kvien TK: Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2010, 69: 671-676. 10.1136\/ard.2009.113308.","journal-title":"Ann Rheum Dis"},{"key":"4079_CR13","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/art.30367","volume":"63","author":"M Bulatovic","year":"2011","unstructured":"Bulatovic M, Heijstek MW, Verkaaik M, van Dijkhuizen EH, Armbrust W, Hoppenreijs EP, Kamphuis S, Kuis W, Egberts TC, Sinnema G, Rademaker CM: High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum. 2011, 63: 2007-2013. 10.1002\/art.30367.","journal-title":"Arthritis Rheum"},{"key":"4079_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/01.rhu.0000173616.81928.44","volume":"11","author":"HI Brunner","year":"2005","unstructured":"Brunner HI, Johnson AL, Barron AC, Passo MH, Griffin TA, Graham TB, Lovell TJ: Gastrointestinal symptoms and their association with health-related quality of life of children with juvenile rheumatoid arthritis: validation of a gastrointestinal symptom questionnaire. J Clin Rheumatol. 2005, 11: 194-204. 10.1097\/01.rhu.0000173616.81928.44.","journal-title":"J Clin Rheumatol"},{"key":"4079_CR15","first-page":"218","volume":"22","author":"Rheumatoid Arthritis Clinical Trial Archive Group","year":"1995","unstructured":"Rheumatoid Arthritis Clinical Trial Archive Group: The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol. 1995, 22: 218-223.","journal-title":"J Rheumatol"},{"key":"4079_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/rheumatology\/35.5.453","volume":"35","author":"C Bologna","year":"1996","unstructured":"Bologna C, Viu P, Jorgensen C, Sany J: Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. Br J Rheumatol. 1996, 35: 453-457. 10.1093\/rheumatology\/35.5.453.","journal-title":"Br J Rheumatol"},{"key":"4079_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1521-6942(02)90234-2","volume":"16","author":"KJ Murray","year":"2002","unstructured":"Murray KJ, Lovell DJ: Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol. 2002, 16: 361-378.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"4079_CR18","first-page":"179","volume":"31","author":"K Alsufyani","year":"2004","unstructured":"Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN: The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol. 2004, 31: 179-182.","journal-title":"J Rheumatol"},{"key":"4079_CR19","first-page":"1830","volume":"27","author":"A Ravelli","year":"2000","unstructured":"Ravelli A, Martini A: Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol. 2000, 27: 1830-1833.","journal-title":"J Rheumatol"},{"key":"4079_CR20","first-page":"480","volume":"25","author":"A van der Meer","year":"2007","unstructured":"van der Meer A, Wulffraat NM, Prakken BJ, Gijsbers B, Rademaker CM, Sinnema G: Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol. 2007, 25: 480-485.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4413.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar4413\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4413.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:06:53Z","timestamp":1728382013000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar4413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,18]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,12]]}},"alternative-id":["4079"],"URL":"https:\/\/doi.org\/10.1186\/ar4413","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,18]]},"assertion":[{"value":"29 March 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R217"}}